Home › Astrocytoma › Massachusetts
Astrocytoma clinical trials in Massachusetts
13 studies for Astrocytoma are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Targeted Pediatric High-Grade Glioma Therapy
- Dana-Farber Cancer Institute, Boston
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Serial MRI Scans During Radiation Therapy
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04188535Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
- Tufts Medical Center, Boston
RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT07215910Study of Olutasidenib and Temozolomide in HGG
- Susan Chi, Boston
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 12, 2026 · NCT05417594Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Dana-Farber Cancer Institute, Boston
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Implantable Microdevice In Primary Brain Tumors
- Brigham and Women's Hospital, Boston
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 23, 2025 · NCT04135807The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Feb 28, 2024 · NCT06283927The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
- Massachusetts General Hospital, Boston
RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Feb 22, 2024 · NCT06118723The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
- Massachusetts General Hospital, Boston
RecruitingObservational study
Up to age 90 · All sexes · Updated Feb 22, 2024 · NCT06273176From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.